TeneoBio Company Profile: Acquisition & Investors

TeneoBio Overview

Founded
2009

Status
Acquired/Merged

Employees
52

Latest Deal Type
M&A

Latest Deal Amount
$900M

Investors
1

TeneoBio General Information

Description

Operator of a biotechnology company intended to develop biologics, human heavy-chain antibodies for the treatments of cancer, autoimmunity, and infectious diseases. The company's platform comprises genetically engineered animals, next-generation sequencing, bioinformatics, and throughput vector assembly technologies that rapidly identifies large numbers of unique binding molecules specific for therapeutic targets of interest, thereby enabling patients immune system to overcome diseases and disorders.

Contact Information

Website

www.teneobio.com

Formerly Known As

HCO Antibody

Ownership Status

Acquired/Merged

Financing Status

Formerly VC-backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Acquirer

Amgen

Primary Office

7999 Gateway Boulevard
Newark, CA 94560
United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TeneoBio Valuation & Funding

Deal Type	Date	Amount	Raised to Date	Post-Val	Status	Stage
3. Merger/Acquisition	19-Oct-2021	$900M	000.00	00000	Completed	Generating Revenue
2. Later Stage VC (Series A2)	08-Jan-2018	0000	000.00	0000	Completed	Generating Revenue
1. Later Stage VC (Series A1)	03-May-2016	$3.5M	$3.5M	00.00	Completed	Clinical Trials - General

To view TeneoBio’s complete valuation and funding history, request access »

TeneoBio Cap Table

Stock	# of Shares Authorized	Par Value	Dividend Rate (%)	Original Issue Price	Liquidation	Liquidation Pref. Multiple	Conversion Price	% Owned
Series A-2	00,000,000	00.000000	00.00	00.00	00.00	00	00.00	000
Series A-1	0,000,000	00.000000		00.00	00.00	00	00.00	00.000

To view TeneoBio’s complete cap table history, request access »

TeneoBio Comparisons

Description

Primary
Industry

HQ Location

Employees

Total Raised

Post Valuation

Last Financing Details

Operator of a biotechnology company intended to develop biologics, human heavy-chain antibodies for the treatments of ca

Biotechnology

Newark, CA

52 As of 2021

000.00

0000 0000-00-00

000000&0 000.00

0000 000

liquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillu

0000 000000000

Brisbane, CA

00 As of 0000

00000

0000 0000-00-00

00000000000 00000

00000000

lla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mol

0000 000000000

San Carlos, CA

00 As of 0000

00000

0000 0000-00-00

00000000000 00000

Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TeneoBio Competitors (3)

Company Name	Financing Status	Location	Employees	Total Raised	Last Financing Amount
Arch Oncology	Venture Capital-Backed	Brisbane, CA	00	00000	00000
00000000	Venture Capital-Backed	San Carlos, CA	00	00000	00000
00000000 000000000	Venture Capital-Backed	Haddonfield, NJ	0	000.00	000.00

You’re viewing 3 of 3 competitors. Get the full list »

TeneoBio Patents

63
Total Documents Applications and Grants
000
Total Patents Families
000
Granted
12
Pending
000
Expiring in next 12 mo

TeneoBio Recent Patent Activity

Publication ID	Patent Title	Status	First Filing Date	Technology (CPC)
US-20210047402-A1	Multispecific heavy chain antibodies binding to cd22 and cd3	Pending	14-Jun-2019	00000000000
CA-3133654-A1	Heavy chain antibodies binding to psma	Pending	05-Apr-2019	00000000000
AU-2019367218-A1	Heavy chain antibodies binding to cd38	Pending	26-Oct-2018	00000000000
CA-3100232-A1	Heavy chain antibodies binding to cd38	Pending	26-Oct-2018	00000000000
EP-3870611-A1	Heavy chain antibodies binding to cd38	Pending	26-Oct-2018	C07K16/2896